Streetbeat News

BIOS

BioPlus Acquisition Corp

Open

10.79

Mkt cap

209M

Volume

5.6K

High

10.80

P/E Ratio

51.40

52-wk high

11.68

Low

10.79

Div yield

N/A

52-wk low

10.12

Avertix Medical, Inc. and BIOS Acquisition Corporation have mutually agreed to terminate their proposed business combination. Avertix is a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, while BIOS is a special purpose acquisition company.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:38 am

Heart & Rhythm Institute of Trinity has partnered with Avertix to improve cardiac care and patient monitoring. The Avertix Guardian System, the first FDA approved implantable heart attack warning system, is now available at the Heart & Rhythm Institute of Trinity. Dr. Luis R. Annoni-Suau, MD, FACC and Dr. Carlos J. Bayron have successfully performed the first two Guardian implants.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 12:33 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.